DE602004023721D1 - Zusammensetzungen und methoden für die behandlung von herzerkrankungen - Google Patents

Zusammensetzungen und methoden für die behandlung von herzerkrankungen

Info

Publication number
DE602004023721D1
DE602004023721D1 DE602004023721T DE602004023721T DE602004023721D1 DE 602004023721 D1 DE602004023721 D1 DE 602004023721D1 DE 602004023721 T DE602004023721 T DE 602004023721T DE 602004023721 T DE602004023721 T DE 602004023721T DE 602004023721 D1 DE602004023721 D1 DE 602004023721D1
Authority
DE
Germany
Prior art keywords
compositions
treatment
methods
heart diseases
heart
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004023721T
Other languages
English (en)
Inventor
Vinrod Sharma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medtronic Inc
Original Assignee
Medtronic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medtronic Inc filed Critical Medtronic Inc
Publication of DE602004023721D1 publication Critical patent/DE602004023721D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/362—Heart stimulators
    • A61N1/3629—Heart stimulators in combination with non-electric therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
DE602004023721T 2003-07-24 2004-07-22 Zusammensetzungen und methoden für die behandlung von herzerkrankungen Expired - Lifetime DE602004023721D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/626,159 US20050021089A1 (en) 2003-07-24 2003-07-24 Compositions and methods for treating cardiac dysfunction
PCT/US2004/023717 WO2005009477A1 (en) 2003-07-24 2004-07-22 Compositions and methods for treating cardiac dysfunction

Publications (1)

Publication Number Publication Date
DE602004023721D1 true DE602004023721D1 (de) 2009-12-03

Family

ID=34080358

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004023721T Expired - Lifetime DE602004023721D1 (de) 2003-07-24 2004-07-22 Zusammensetzungen und methoden für die behandlung von herzerkrankungen

Country Status (5)

Country Link
US (1) US20050021089A1 (de)
EP (1) EP1648521B1 (de)
CA (1) CA2533858A1 (de)
DE (1) DE602004023721D1 (de)
WO (1) WO2005009477A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080260705A1 (en) * 2004-03-22 2008-10-23 The Johns Hopkins University Preventing Arrhythmias Associated with Cell Transplantation
US8565898B2 (en) * 2005-04-28 2013-10-22 Medtronic, Inc. Rate control during AF using cellular intervention to modulate AV node
EP1909895A4 (de) * 2005-07-21 2009-04-22 Univ Columbia Tandem-herzschrittmacher-system
US8236296B2 (en) * 2005-07-21 2012-08-07 The Trustees Of Columbia University In The City Of New York Biological bypass bridge with sodium channels, calcium channels and/or potassium channels to compensate for conduction block in the heart
WO2008043099A2 (en) * 2006-10-06 2008-04-10 Medtronic, Inc. Hybrid pacing system
US7787949B2 (en) * 2006-10-30 2010-08-31 Medtronic, Inc. Biological pacemaker compositions and systems incorporating interstitial cells of Cajal
US7778705B2 (en) * 2006-10-31 2010-08-17 Medtronic, Inc. Electronic and biological pacemaker systems
US8076305B2 (en) * 2006-11-30 2011-12-13 Medtronic, Inc. Biological pacemakers including mutated hyperpolarization-activated cyclic nucleotide-gated (HCN) channels
US20080280341A1 (en) * 2007-05-08 2008-11-13 Kenknight Bruce System And Method For Local Field Stimulation
US8224443B2 (en) * 2007-05-08 2012-07-17 Cardiac Pacemakers, Inc. Method for controlling pacemaker therapy
US8442631B2 (en) * 2007-05-08 2013-05-14 Cardiac Pacemakers, Inc. System and method for determining the origin of a sensed beat
US9150832B2 (en) * 2007-05-08 2015-10-06 Cardiac Pacemakers, Inc. Cell training for local field stimulation
US20090054828A1 (en) * 2007-08-22 2009-02-26 Cardiac Pacemakers, Inc. Systems for transient conduction control
US8311620B2 (en) * 2007-08-22 2012-11-13 Cardiac Pacemakers, Inc. Methods and apparatus to treat and prevent atrial tachyarrhythmias
WO2009111755A2 (en) * 2008-03-07 2009-09-11 The Trustees Of Columbia University In The City Of New York Compensating for atrioventricular block using a nucleic acid encoding a sodium channel or gap junction protein
US20110144028A1 (en) * 2009-12-11 2011-06-16 Vinod Sharma Modulating cellular electrophysiology
US8639323B2 (en) 2010-11-01 2014-01-28 Medtronic, Inc. System and apparatus to monitor biopacemaker maturation
US9913865B2 (en) * 2015-12-28 2018-03-13 Ingeneron Inc. Induced pacemaker and Purkinje cells from adult stem cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214620B1 (en) * 1998-09-29 2001-04-10 The Johns Hopkins University Inducible genetic suppression of cellular excitability
CA2421584C (en) * 2000-09-06 2013-12-31 Johns Hopkins University Gene therapy for cardiac arrythmias
EP1409510A4 (de) * 2001-04-27 2004-09-08 Univ Johns Hopkins Biologischer herzschrittmacher

Also Published As

Publication number Publication date
CA2533858A1 (en) 2005-02-03
US20050021089A1 (en) 2005-01-27
WO2005009477A1 (en) 2005-02-03
EP1648521A1 (de) 2006-04-26
EP1648521B1 (de) 2009-10-21

Similar Documents

Publication Publication Date Title
ATE374196T1 (de) Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen
ATE441417T1 (de) Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
DE602004023721D1 (de) Zusammensetzungen und methoden für die behandlung von herzerkrankungen
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
DE60233414D1 (de) Kombinationen für die behandlung entzündlicher erkrankungen
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
DE60325209D1 (de) Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
ATE458753T1 (de) Methoden der verhinderung und behandlung der alzheimer'schen krankheit
ATE544748T1 (de) Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen
DE602005013116D1 (de) Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE551340T1 (de) Azabicyclisch- substituierte annelierte heteroaryl-verbinungen für die behandlung von krankheiten
DE60335560D1 (de) Zusammensetzungen enthaltend zitronensäure zur behandlung von nagelpilzerkrankungen
DE602006018583D1 (de) Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
ATE519488T1 (de) Aminopyrazin-analoga zur behandlung von glaukomen und anderen durch rho-kinase verursachten krankheiten
DE602004028763D1 (de) Te zur behandlung von virenerkrankungen
ATE502642T1 (de) Kombinationen für die behandlung von immun- entzündlichen erkrankungen
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
DE60239218D1 (de) Synergistische zusammensetzungen für die behandlung von saatgut
ATE440866T1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
DE60204951D1 (de) Ccr5 antagonisten verwendbar für die behandlung von aids
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
ATE422498T1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems

Legal Events

Date Code Title Description
8364 No opposition during term of opposition